Physician profile
Michael Sears
NPI 1902863152
$3,565.67
in general payments reported to CMS, 2019-2025
12 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2021: $336 · 2022: $1,030 · 2023: $307 · 2024: $269 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $1,165.94 | 2019 | |
| Stryker Corporation | $949.50 | 2021-2025 | Citrefix, Flexband, Phalinx |
| Treace Medical Concepts, INC. | $859.14 | 2022-2025 | |
| Urgo Medical North America, LLC | $330.51 | 2023-2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2, Urgoclean Ag |
| Organogenesis INC. | $119.44 | 2023-2025 | Puraply Wound Matrix, Puraply |
| Kerecis Limited | $39.96 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Next Science LLC | $25.32 | 2023 | Xperience, Surgx, Blastx |
| Smith+Nephew, INC. | $18.55 | 2024 | Collagenase Santyl |
| Musculoskeletal Transplant Foundation INC. | $16.96 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.87 | 2019 | |
| Hydrofera LLC | $13.69 | 2025 | Hydrofera Blue |
| Glaxosmithkline, LLC. | $12.79 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.